<DOC>
	<DOCNO>NCT00563472</DOCNO>
	<brief_summary>This open study 50 young , healthy , female volunteer . Women want participate use hormonal contraception stop use hormonal contraceptive wait first spontaneous menstruation ( i.e . wash-out cycle ) . Women use hormonal contraception wait next menstruation . From 9th day start menstruation onwards follicle growth monitor ultrasonography ovulation occur day 24 start menses . Women ovulate within 24 day start menses eligible participate stratify one 4 group : 10 mg estetrol ( E4 ) alone , 20 mg E4 alone , 20 mg E4 combine 150 mcg desogestrel 20 mg E4 combine 200 mg progesterone . The subject treat 28 day . Treatment start first day menses pre-treatment cycle . During study period ( 28 day ) activity hypothalamic-pituitary-ovarian ( HPO ) axis investigate measure follicular development use ultrasonography determine serum concentration Follicle Stimulating Hormone ( FSH ) , Luteinising Hormone ( LH ) , estradiol ( E2 ) Progesterone ( P ) .</brief_summary>
	<brief_title>Feasibility Study Into Contraceptive Effect Estetrol</brief_title>
	<detailed_description />
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>At least 18 year old 40 year age Willing use barrier method contraception washout cycle , pretreatment cycle , period study drug administration , period lynestrenol intake ( applicable ) , 14 day thereafter followup visit 14days period end followup visit . Women ovulate pretreatment cycle day 24 ( Â±1 ) start menses , subsequent P concentration &gt; 16 nmol/l whose next menstruation start within 6 day ovulation Body Mass Index &gt; 18 &lt; 30 kg/m2 Good physical mental health Both ovaries visible upon ultrasonography Willing give inform consent write Clinically significant abnormal result routine hematology , serum biochemistry , urinanalysis , and/or ECG opinion Investigator screening . Known suspected pregnancy Lactation Pregnancy accurate hormonal contraceptive use Known suspect breast cancer history breast cancer Clinically significant abnormality uterus and/or ovary detect examination and/or ultrasound ( nonphysiological ovarian mass significant uterine pathology ) . A cervical smear clinically relevant abnormal cytology within one year study start . Previous use depot progestogen preparation last 6 month . Contraindications contraceptive steroid : history , exist thromboembolic , cardiovascular cerebrovascular disorder history , exist condition predispose , prodromi , thrombosis know defect blood coagulation system ( e.g . deficiency ATIII , protein C , S , APC resistance ) heterozygous mutation coagulation factor II and/or positive factor V Leiden presence severe one risk factor vascular disease ( e.g . dyslipoproteinaemia ; diabetes mellitus ; hyperhomocysteinaemia ; systemic lupus erythematosus ; chronic inflammatory bowel disease ; antiphospholipid antibody ; smoke ; venous thromboembolism sibling parent age 50 , arterial disease sibling parent age 35 ; within 2 week full remobilisation follow surgery ) hypertension , i.e . systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg disturbance liver function : e.g . cholestatic jaundice , history jaundice pregnancy jaundice due previous oestrogen use , Rotor syndrome DubinJohnson syndrome know suspected hormonedependent tumour endometrial hyperplasia undiagnosed vaginal bleeding porphyria history pregnancy previous hormoneuse severe pruritus , herpes gestationis deterioration otosclerosis Use one follow medication : sex steroid medication study use present within 2 month start study medication : hydantoin , barbiturate , primidone , carbamazepine , oxcarbazepine , topiramate , troglitazone , felbamate , rifampicin , rifabutin , griseofulvin St. John 's wort ( Hypericum perforatum ) Status postpartum postabortion within period 2 month study start Administration investigational drug within 3 month start study medication A history ( within 12 month ) alcohol drug abuse A know hypersensitivity one component study medication ( eg arachisoil lactosis )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Healthy female volunteer participate study</keyword>
</DOC>